November 21st 2024
In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.
October 21st 2024
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
CG0070 Provides Durable Responses in Certain Patients with Non-Muscle Invasive Bladder Cancer
June 21st 2022In an interview with Targeted Oncology, Roger Li, MD, discussed the use of the CG0070 in combination with pembrolizumab and nivolumab for patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.
Read More
BLA Submitted to the FDA for N-803 Plus BCG in BCG-Unresponsive Bladder Cancer
May 25th 2022A biologics license application has been submitted to the FDA for N-803 plus Bacillus Calmette-Guérin as treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer in situ with or without Ta or T1 disease.
Read More
More Analyses Explore Benefit of Frontline Maintenance Avelumab Plus BSC in Advanced UC
May 19th 2022In an interview with Targeted Oncology, Joaquim Bellmunt, MD, PhD, discussed the long-term overall survival data for first-line maintenance avelumab in mUC presented at the AUA 2022 Annual Meeting and a sub-analysis of the JAVELIN Bladder 100 trial being read out at the upcoming 2022 ASCO Annual Meeting.
Read More
Mitomycin Gel Maintains QOL in Patients With Low Grade Non-Muscle Invasive Bladder Cancer
May 16th 2022Health-related quality-of-life outcomes were maintained among patients with low grade non-muscle invasive bladder cancer who were treated with UGN-102, a chemoablative reverse thermal gel as a primary approach in the single-arm phase 2b Optima II trial.
Read More
Infigratinib Demonstrates Activity and Tolerability of FGFR Inhibition in Urothelial Carcinoma
May 16th 2022Interim results from a biomarker-informed preoperative study of infigratinib demonstrated substantial activity and tolerability in patients with localized upper tract urothelial carcinoma, according to findings of a phase 1b trial.
Read More
Results of CG0070 Combined With Pembrolizumab in BCG-Unresponsive NMIBC
May 16th 2022Roger Li, MD, shares the results of the phase 2 CORE1 clinical trial, which evaluated CG0070 in combination with pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
Watch
Nintedanib With Neoadjuvant Chemotherapy Shows No PCR Benefit in MIBC
May 2nd 2022Nintedanib plus neoadjuvant chemotherapy did not achieve improvement in pathologic complete response in patients with muscle invasive bladder cancer in the phase 2 NEOBLADE study, but the study provided important survival signals.
Read More
Siefker-Radtke Discusses the Role of Antibody-Drug Conjugates in Urothelial Carcinoma
March 25th 2022During a Targeted Oncology case-based roundtable event, Arlene Siefker-Radtke discussed the second-line treatment options for a patient with urothelial carcinoma and the EV-301 trial of enfortumab vedotin.
Read More